Page 29 - GPD-2-4

Gene & Protein in Disease The roles and mechanisms of ETS1 in diseases

and miR-326 in CD19(+)B cells in the pathogenesis of of MicroRNA-326 in a NOD.H-2(h4) mouse model of
patients with systemic lupus erythematosus. Clin Rheumatol, autoimmune thyroiditis. Front Immunol, 12: 620916.
38(4): 1031–1038.
https://doi.org/10.3389/fimmu.2021.620916
https://doi.org/10.1007/s10067-018-4371-0
32. Li L, Ma X, Zhao YF, et al., 2020, MiR-1-3p facilitates Th17
21. Moisan J, Grenningloh R, Bettelli E, et al., 2007, Ets-1 is differentiation associating with multiple sclerosis via targeting
a negative regulator of Th17 differentiation. J Exp Med, ETS1. Eur Rev Med Pharmacol Sci, 24(12): 6881–6892.
204(12): 2825–2835.
https://doi.org/10.26355/eurrev_202006_21678
https://doi.org/10.1084/jem.20070994
33. Luo Y, Yang H, Wan Y, et al., 2022, Endothelial ETS1
22. Na SY, Park MJ, Park S, et al., 2016, MicroRNA-155 regulates inhibition exacerbate blood-brain barrier dysfunction
the Th17 immune response by targeting Ets-1 in Behcet’s in multiple sclerosis through inducing endothelial-to-
disease. Clin Exp Rheumatol, 34(6 Suppl 102): S56–S63. mesenchymal transition. Cell Death Dis, 13(5): 462.
23. Luo W, Mayeux J, Gutierrez T, et al., 2014, A balance https://doi.org/10.1038/s41419-022-04888-5
between B cell receptor and inhibitory receptor signaling 34. Buggy Y, Maguire TM, McGreal G, et al., 2004,
controls plasma cell differentiation by maintaining optimal Overexpression of the Ets-1 transcription factor in human
Ets1 levels. J Immunol, 193(2): 909–920.
breast cancer. Br J Cancer, 91(7): 1308–1315.
https://doi.org/10.4049/jimmunol.1400666
https://doi.org/10.1038/sj.bjc.6602128
24. Kim CJ, Lee CG, Jung JY, et al., 2018, The transcription factor 35. Li Y, Wu T, Peng Z, et al., 2022, ETS1 is a prognostic
Ets1 suppresses T follicular helper type 2 cell differentiation biomarker of triple-negative breast cancer and promotes the
to halt the onset of systemic lupus erythematosus. Immunity, triple-negative breast cancer progression through the YAP
49(6): 1034–1048.e8.
signaling. Am J Cancer Res, 12(11): 5074–5084.
https://doi.org/10.1016/j.immuni.2018.10.012
36. Fang LW, Kao YH, Chuang YT, et al., 2019, Ets-1 enhances
25. Sunshine A, Goich D, Stith A, et al., 2019, Ets1 controls tumor migration through regulation of CCR7 expression.
the development of B cell autoimmune responses in a cell- BMB Rep, 52(9): 548–553.
intrinsic manner. Immunohorizons, 3(7): 331–340.
https://doi.org/10.5483/BMBRep.2019.52.9.232
https://doi.org/10.4049/immunohorizons.1900033
37. Peng P, Ren Y, Wan F, et al., 2023, Sculponeatin A promotes
26. Xia Y, Tao JH, Fang X, et al., 2018, MicroRNA-326 the ETS1-SYVN1 interaction to induce SLC7A11/xCT-
upregulates B cell activity and autoantibody production dependent ferroptosis in breast cancer. Phytomedicine,
in lupus disease of MRL/lpr mice. Mol Ther Nucleic Acids, 117: 154921.
11: 284–291.
https://doi.org/10.1016/j.phymed.2023.154921
https://doi.org/10.1016/j.omtn.2018.02.010
38. Furlan A, Vercamer C, Heliot L, et al., 2019, Ets-1 drives
27. Chen L, Huang Z, Yang B, et al., 2015, Association of E26 breast cancer cell angiogenic potential and interactions
transformation specific sequence 1 variants with rheumatoid between breast cancer and endothelial cells. Int J Oncol,
arthritis in Chinese han population. PLoS One, 10(8): 54(1): 29–40.
e0134875.
https://doi.org/10.3892/ijo.2018.4605
https://doi.org/10.1371/journal.pone.0134875
39. Ballschmieter P, Braig M, Lindemann RK, et al., 2003, Splicing
28. Yang B, Luo L, Chen L, et al., 2021, ETS1 polymorphism variant DeltaVII-Ets1 is downregulated in invasive Ets1-
rs73013527 in relation to serum RANKL levels among expressing breast cancer cells. Int J Oncol, 22(4): 849–853.
patients with RA. Medicine (Baltimore), 100(5): e24562.
https://doi.org/10.3892/ijo.22.4.849
https://doi.org/10.1097/MD.0000000000024562
40. Furlan A, Vercamer C, Bouali F, et al., 2014, Ets-1 controls
29. Yan M, Komatsu N, Muro R, et al., 2022, ETS1 is a key breast cancer cell balance between invasion and growth. Int
transcription factor that drives RANKL-expressing, tissue- J Cancer, 135(10): 2317–2328.
destructive fibroblasts. Nat Immunol, 23(9): 1303–1304.
https://doi.org/10.1002/ijc.28881
https://doi.org/10.1038/s41590-022-01298-9
41. Kim GC, Lee CG, Verma R, et al., 2020, ETS1 suppresses
30. Zhao N, Zou H, Qin J, et al., 2018, MicroRNA-326 tumorigenesis of human breast cancer via trans-activation
contributes to autoimmune thyroiditis by targeting the Ets-1 of canonical tumor suppressor genes. Front Oncol, 10: 642.
protein. Endocrine, 59(1): 120–129.
https://doi.org/10.3389/fonc.2020.00642
https://doi.org/10.1007/s12020-017-1465-4
42. Nazir SU, Kumar R, Singh A, et al., 2019, Breast cancer
31. Zhao N, Wang Z, Cui X, et al., 2021, In vivo inhibition invasion and progression by MMP-9 through Ets-1

Volume 2 Issue 4 (2023) 8 https://doi.org/10.36922/gpd.2141